New drug FL115 tested in advanced cancer patients
NCT ID NCT07131189
First seen Jan 09, 2026 · Last updated May 15, 2026 · Updated 23 times
Summary
This early-phase study tests a new drug called FL115 in 30 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. Participants receive FL115 alone, and the study includes two parts: dose escalation and dose expansion.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED/METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100142, China
-
Shandong Cancer Hospital
Jinan, Shandong, 250117, China
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510000, China
Conditions
Explore the condition pages connected to this study.